Product Description
Mechanisms of Action: PI3K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/01/2023 |
PubMed |
PI3K delta inhibitor PI-3065 induces apoptosis in hepatocellular carcinoma cells by targeting survivin. |
|
11/01/2022 |
PubMed |
Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion. |
|
10/01/2020 |
PubMed |
Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3. |